Ritamix Global Limited reported audited results for the year ended 31 December 2025, showing steady top-line expansion and margin improvement.
Revenue and Profitability • Group revenue increased 4.7% year on year to RM128.29 million, driven by: – Distribution revenue up 5.5% to RM99.99 million, supported by a new product range. – Manufacturing revenue up 1.8% to RM28.30 million on stronger vitamin and mineral premix sales.
• Gross profit rose 8.5% to RM28.02 million, lifting the gross margin to 21.8% (FY2024: 21.0%). • Profit before tax advanced 13.3% to RM12.98 million, while net profit attributable to shareholders grew 12.1% to RM9.27 million. • Basic earnings per share increased to 1.99 sen from 1.76 sen.
Cost and Expense Highlights • Cost of sales increased 3.6% to RM100.27 million. • Selling and distribution costs were essentially flat at RM2.76 million. • Administrative and other operating expenses edged down 1.3% to RM16.10 million. • Other income and gains fell 25.7% to RM3.97 million, mainly on lower bank interest and investment returns.
Segment Performance • Animal feed additives (manufacturing and distribution) contributed RM104.45 million in revenue and RM21.29 million in gross profit. • Human food ingredient distribution generated RM23.84 million in revenue and RM6.73 million in gross profit.
Balance Sheet and Liquidity • Cash and cash equivalents stood at RM43.51 million (FY2024: RM60.32 million) after a RM29.52 million special dividend paid in January 2025. • The group carried no bank borrowings; lease liabilities totalled RM1.87 million. • Current ratio improved to 13.0x (FY2024: 4.0x); gearing remained low at 1.3%. • Net assets attributable to shareholders increased to RM143.17 million from RM134.67 million.
Cash Flow • Operating activities generated RM14.06 million in net cash (FY2024: outflow of RM0.19 million). • Capital expenditure totalled RM1.44 million, mainly for property, plant and equipment. • Financing outflows were RM30.40 million, dominated by the special dividend and lease repayments.
Dividend No final dividend was proposed for FY2025.
Use of IPO Proceeds At 31 December 2025, RM56.50 million of net proceeds remained unutilised, earmarked mainly for a new manufacturing plant, potential industry investments, an ERP system, a testing laboratory and additional headcount. Management expects full deployment by 31 December 2026.
Post-Year-End Events • In January 2026, Ritamix acquired 100% of Gladron Pte. Ltd. for SGD100 to expand into Singapore’s pet-related product market. • Management is monitoring potential geopolitical risks stemming from recent Middle East tensions; no material impact has been identified to date.
Outlook Management cited continued cost optimisation and selective product expansion as key focus areas, while maintaining a conservative capital structure to support planned capacity and system upgrades.
Comments